Findings showed that remibrutinib outperformed teriflunomide in the REMODEL-1 and REMODEL-2 phase 3 trials among adults with relapsing MS, lowering relapse rates and MRI lesions with a favorable ...
In recognition of SMA Awareness Month, NeurologyLive® spoke with neuromuscular experts about how multidisciplinary care is ...
Diagnosing multiple sclerosis (MS) has changed considerably in recent years for neurologists in the field, with revised criteria now allowing clinicians to identify the disease ea ...
Phase 1b/2 findings showed that the investigational anti-amyloid monoclonal antibody ABBV-916 produced dose-dependent ...
A phase 1 feasibility trial found that placing GammaTile radiation therapy directly into the surgical cavity during ...
Casey*, now in his 30s, recalls that period clearly. As a high school senior, Casey ate dinner after sports practice, went straight to bed, and spent up to 12 hours each night trying to sleep. Despite ...
The FDA was busy early this month, during the week of August 23, 2026, making a number of decisions on potential new ...
NeurologyLive Brain Games is a weekly, Sunday-morning quiz series featuring three questions authored by clinicians and ...
In honor of SMA Awareness Month, held annually throughout August, get caught up on the latest news in spinal muscular atrophy ...
FDA has cleared C2N Diagnostics' PrecivityAD2 blood test for adults 40 years and older with cognitive symptoms, offering fast amyloid and tau insight to guide diagnosis and trials in Alzheimer disease ...
The vice president of Neuroscience and Vaccines at Takeda discusses the clinical significance of oveporexton's FDA approval ...
The FDA has been busy this week, making multiple decisions over just a few days. The administration kicked off the week by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results